| Catalog No. | HS840016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Chimeric |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Membrane antigen MN, P54/58N, Carbonic anhydrase 9, Renal cell carcinoma-associated antigen G250, CA-IX, CAIX, pMW1, Carbonic anhydrase IX, RCC-associated antigen G250, Carbonate dehydratase IX, CA9, MN, G250 |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q16790 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -329°C. |
|---|
| Alternate Names | WX-G250,cG250,CAS:916138-87-9 |
|---|
| Background | Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
